Close Menu

NEW YORK – Arcellx said on Tuesday that the US Food and Drug Administration has accepted its IND application for the autologous T-cell therapy ACLX-001, and that the firm accordingly plans to begin a Phase I clinical trial of Arcellx for multiple myeloma patients in the second half of 2021.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.